Literature DB >> 10772417

Sequence of molecular genetic events in colorectal tumorigenesis.

P Laurent-Puig1, H Blons, P H Cugnenc.   

Abstract

Intensive screening for genetic alteration in colorectal cancer led to the identification of two types of colorectal tumours that are distinct by their carcinogenesis processes. The first group, named LOH (for loss of heterozygosity)-positive, is characterized by hyperploidy and allelic losses involving preferentially chromosome 18q and chromosome 17p. More than two-thirds of colorectal cancers belong to this group. The second group, called multiple microsatellite loci (MSI)-positive cancers, is characterized by genetic instability at microsatellite loci. Although colorectal cancer cells are characterized by specific microsatellite alterations, the same four different signalling pathways, WNT/Wingless pathway, K-ras pathway, transforming growth factor (TGF)beta pathway and p53 pathway, could be implicated in tumour progression. The WNT/Wingless pathway could be altered in two different ways according to whether the cancer cells belong to the group of LOH-positive or MSI-positive tumours. LOH-positive tumours activate the WNT/Wingless signalling pathway through an adenomatous polyposis coli (APC) mutation, whereas the MSI-positive tumours activate this pathway through a beta-catenin stabilizing mutation. Beta-catenin and APC mutations were observed as early as the adenomatous stage of colorectal neoplasia. In TGFbeta pathways LOH-positive tumours inactivated SMAD2 (similar to mother against decapentaplegic drosophilia) or SMAD4, whereas in MSI-positive tumours the TGFbeta type II receptor is frequently deleted. Alteration of these genes correlated closely with the progression of the adenoma to cancer. In the p53 pathway LOH-positive tumours showed frequent p53 mutation, whereas MSI-positive tumours demonstrated BAX (BCL-2-associated X protein)-inactivating mutation. These alterations contribute to the adenoma-carcinoma transition.

Entities:  

Mesh:

Year:  1999        PMID: 10772417

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  18 in total

1.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

Review 2.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 3.  AP-1 and colorectal cancer.

Authors:  Reiko Ashida; Kazunari Tominaga; Eiji Sasaki; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Kazuhide Higuchi; Shokei Mitsuyama; Hiroshi Iwao; Tetsuo Arakawa
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

4.  Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines.

Authors:  Marion M Schuierer; Elisabeth Graf; Ken-Ichi Takemaru; Wolfgang Dietmaier; Anja-Katrin Bosserhoff
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

5.  Down-regulation of beta-catenin by activated p53.

Authors:  E Sadot; B Geiger; M Oren; A Ben-Ze'ev
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

6.  A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer.

Authors:  Silvia Valtorta; Gabriella Nicolini; Farida Tripodi; Cristina Meregalli; Guido Cavaletti; Federica Avezza; Luca Crippa; Gloria Bertoli; Francesca Sanvito; Paola Fusi; Roberto Pagliarin; Fulvia Orsini; Rosa Maria Moresco; Paola Coccetti
Journal:  Invest New Drugs       Date:  2014-08-19       Impact factor: 3.850

7.  Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice.

Authors:  Lillian Maggio-Price; Piper Treuting; Weiping Zeng; Mark Tsang; Helle Bielefeldt-Ohmann; Brian M Iritani
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 8.  [Clinical, pathological and molecular prognostic factors in colorectal carcinomas].

Authors:  S E Baldus
Journal:  Pathologe       Date:  2003-01-21       Impact factor: 1.011

9.  Acetaldehyde disrupts tight junctions in Caco-2 cell monolayers by a protein phosphatase 2A-dependent mechanism.

Authors:  Mitzi Dunagan; Kamaljit Chaudhry; Geetha Samak; R K Rao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-11       Impact factor: 4.052

10.  Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression.

Authors:  Florence Jourdan; Nicole Sebbagh; Eva Comperat; Najat Mourra; Antoine Flahault; Sylviane Olschwang; Alex Duval; Richard Hamelin; Jean-François Flejou
Journal:  Virchows Arch       Date:  2003-06-07       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.